oral protein-complex 1 (OXPHOS) inhibitor
200-800 mg QD, phase I, cancer/IPF
from metformin
J. Pharmacol. Exp. Ther.
ImmunoMet Therapeutics
IM156
The ImmunoMet OXPHOS modulator (PC1 inhibitor), IM156, is a derivative of the long-used biguanide diabetes drug, metformin, that appears to have activity in lung fibrosis models. The therapeutic hypothesis for…